The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2012Lead Optimization for a Parkinson's Disease Therapeutic
Objective/Rationale:
CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve... -
Therapeutics Development Initiative, 2011Testing of Ambroxol in the Thy1-Alpha-Synuclein Pre-clinical Model of Parkinson's disease
Objective/Rationale:
Biochemical evidence suggests that blocking the maturation of a natural enzyme, glucocerebrosidase (GCase), can cause the build-up of alpha-synuclein deposits in neurons. Such... -
MJFF Research Grant, 2010Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
Objective/Rationale:
Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association... -
MJFF Research Grant, 2010Technology for Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
We seek to create and enhance a secure database, accessible by collaborators with customizable, user-friendly, web-based entry for clinical, genetic and pedigree information. This... -
MJFF Research Grant, 2009Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
Parkinson’s disease (PD) is a prevalent, heterogeneous disorder with a complex, multifactorial etiology. In Tunisia, North Africa, the burden of genetically-defined LRRK2 G2019S... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.